# OnCo record nct05348577 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05348577/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05348577", "NCT05348577" ;
  schema:name "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)"@en ;
  schema:alternateName "CAPItello280"@en ;
  schema:description "A phase 3 trial of Capivasertib, Docetaxel in prostate cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05348577/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05348577> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-03-25" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .